Article
Obstetrics & Gynecology
Willem Jan van Weelden, Roy I. Lalisang, Johan Bulten, Kristina Lindemann, Heleen J. van Beekhuizen, Hans Trum, Dorry Boll, Henrica M. J. Werner, Luc R. C. W. van Lonkhuijzen, Refika Yigit, David Forsse, Petronella O. Witteveen, Khadra Galaal, Alexandra van Ginkel, Eliana Bignotti, Vit Weinberger, Sanne Sweegers, Judith R. Kroep, Silvia Cabrera, Marc P. L. M. Snijders, Marcia A. Inda, Ane Gerda Z. Eriksson, Camilla Krakstad, Andrea Romano, Anja van de Stolpe, Johanna M. A. Pijnenborg
Summary: This study aimed to improve the efficacy of hormonal therapy in advanced or recurrent endometrial cancer by analyzing hormone receptor expressions and pathway activity. Results showed that using a 50% cutoff level for hormone receptor expression significantly enhanced the prediction of response to hormonal treatment.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Oncology
A. Kulkarni, N. M. Andrews Wright, A. N. Forget, T. Ramsay, R. Mallick, J. I. Weberpals
Summary: The purpose of this study is to determine primary survival endpoints in women with recurrent and metastatic endometrial carcinoma treated with progestins. The study found that there may be a role for progestins in select subgroups of women.
Article
Oncology
Qingli Cui, Yuefeng Mao, Yanhui Hu, Dongyang Ma, Huaimin Liu
Summary: This study explored the efficacy and safety of anlotinib in patients with recurrent or metastatic endometrial cancer. The results showed that anlotinib is effective and well tolerated in this patient population. Age and prior lines of treatment were identified as important factors in predicting progression-free survival and overall survival.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Review
Oncology
Vincent M. Wagner, Floor J. Backes
Summary: Endometrial cancer is a common gynecologic cancer with poor prognosis in recurrent cases. Hormonal therapy, including progesterones and agents targeting the estrogen pathway, is an effective option for patients with low-grade hormone receptor-positive disease who cannot tolerate or prefer to avoid cytotoxic chemotherapy or other targeted therapies. Molecular profiling and ongoing trials are exploring novel hormonal therapy agents.
Review
Oncology
Haider Mahdi, Isabelle Ray-Coquard, Domenica Lorusso, Mansoor Raza Mirza, Bradley J. Monk, Brian Slomovitz
Summary: Endometrial cancer is the most common gynecologic malignancy in developed countries, and its incidence and mortality rates are increasing worldwide. The treatment options for metastatic or recurrent endometrial cancer often come with significant toxicities, while the heterogeneous subgroups of the cancer further complicate treatment decisions and interpretation of clinical trial results. Recent advances in molecular classification can guide treatment decisions and help design more effective therapies in the future.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Stephanie Lheureux, Daniela E. Matei, Panagiotis A. Konstantinopoulos, Ben X. Wang, Ramy Gadalla, Matthew S. Block, Andrea Jewell, Stephanie L. Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor J. Backes, Theresa L. Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Lisa Wang, Xuan Li, Rachel Wildman, Shirin Soleimani, Scott Lien, John Wright, Trevor Pugh, Pamela S. Ohashi, David G. Brooks, Gini F. Fleming
Summary: This study explored the combination of immunotherapy and antiangiogenic agents in the treatment of endometrial cancer. Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer patients. The identification of immunotherapy-pretreated patients based on baseline immune profiling can help determine who might benefit from combination treatment with antiangiogenics.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Heidi Rutten, Cornelia Verhoef, Willem Jan van Weelden, Anke Smits, Joelle Dhanis, Nelleke Ottevanger, Johanna M. A. Pijnenborg
Summary: The treatment strategies for recurrent endometrial cancer should be personalized based on the individual patient and tumor characteristics. Local and locoregional recurrences can be curatively treated with surgery or radiotherapy, while distant recurrences may require palliative systemic therapy. Further studies are needed to assess the effectiveness and toxicity of newer treatment strategies in this challenging condition.
Review
Oncology
Francesca Tronconi, Camilla Nero, Elena Giudice, Vanda Salutari, Lucia Musacchio, Caterina Ricci, Maria Vittoria Carbone, Viola Ghizzoni, Maria Teresa Perri, Floriana Camarda, Marica Gentile, Rossana Berardi, Giovanni Scambia, Domenica Lorusso
Summary: Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and limited treatment options. Platinum-based chemotherapy is currently the main treatment. Recent approvals have been granted for combination therapies, but predictive biomarkers are lacking to identify patients who are most likely to benefit.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Medicine, General & Internal
M. R. Mirza, D. M. Chase, B. M. Slomovitz, R. dePont Christensen, Z. Novak, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L. M. Landrum, L. C. Hanker, A. Stuckey, I. Boere, M. A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M. S. Shahin, S. E. Gill, B. J. Monk, J. Buscema, T. J. Herzog, L. J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R. L. Coleman, M. A. Powell
Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Diocesio Alves Pinto de Andrade, Andrea Paiva Gadelha Guimaraes, Andreia Cristina de Melo, Angelica Nogueira-Rodrigues, Larissa Muller Gomes, Mariana Scaranti, Joyce Maria Lisboa Maia, Alessandra Menezes Morelle, Candice Amorim de Araujo Lima Santos, Cristiano de Padua Souza, Daniela de Freitas, Donato Callegaro Filho, Eduardo Paulino, Elge Werneck Araujo, Juliana Martins Pimenta, Marcela Bonalumi dos Santos, Michelle Samora de Almeida, Ronaldo Pereira Souza, Samantha Cabral, Fernando Cotait Maluf
Summary: Endometrial cancer is a growing concern in several countries due to aging populations, declining fertility rates, and increasing obesity. Molecular characterization of endometrial tumors is leading to the development of novel therapies, and we aimed to provide guidance for medical oncologists managing patients with recurrent or metastatic endometrial cancer in Brazil.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Koji Matsuo, Ling Chen, X. Mona Guo, Lynda D. Roman, Maximilian Klar, Jason D. Wright
Summary: This study examines the trends, characteristics, and outcomes of hormonal therapy (HT) or chemotherapy (CT) for early-stage, low-grade endometrial cancer with malignant peritoneal cytology (MPC). The results show an increasing utilization of HT and decreasing utilization of CT, with neither treatment being associated with short-term overall survival.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Medicine, General & Internal
Emma J. Crosbie, Sarah J. Kitson, Jessica N. McAlpine, Asima Mukhopadhyay, Melanie E. Powell, Naveena Singh
Summary: Endometrial cancer is the most common gynaecological cancer in high income countries, with a global rise in incidence. Obesity is the major underlying cause, posing challenges for diagnosis and treatment. Early presentation with postmenopausal bleeding ensures cure, but advanced cases have poor prognosis. Minimally invasive surgical staging and targeted chemotherapeutic strategies are important advances.
Article
Oncology
Nikolaos A. Trikalinos, Deyali Chatterjee, Kyle Winter, Matthew Powell, Motoyo Yano
Summary: This case study highlights the importance of molecular testing for complex synchronous tumors and emphasizes the need for communication between surgical and medical oncologists in patients with MSI-high cancer. The common genetic lineage in the tumors and successful response to tailored immunotherapy suggest a molecular-based approach to treatment may lead to better understanding and outcomes.
Article
Medicine, General & Internal
N. Colombo, C. Dubot, D. Lorusso, M. Caceres, K. Hasegawa, R. Shapira-Frommer, K. S. Tewari, P. Salman, E. Hoyos Usta, E. Yanez, M. Gumus, M. Olivera Hurtado de Mendoza, V Samouelian, V Castonguay, A. Arkhipov, S. Toker, K. Li, S. M. Keefe, B. J. Monk
Summary: Adding pembrolizumab to chemotherapy significantly improves progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer when compared to placebo. Anemia and neutropenia are the most common grade 3 to 5 adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
C. C. B. Post, A. M. Westermann, I. A. Boere, P. O. Witteveen, P. B. Ottevanger, G. S. Sonke, R. Lalisang, H. Putter, E. Meershoek-Klein Kranenbarg, J. P. B. M. Braak, C. L. Creutzberg, T. Bosse, J. R. Kroep
Summary: The combination of PD-L1 and PARP inhibitors for advanced endometrial cancer showed good tolerability in this trial, however, it did not meet the predefined efficacy endpoint. Some patients had progression-free survival at 6 months, with an objective response rate of 16%, a median progression-free survival of 3.4 months, and a median overall survival of 8.0 months.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Abigail D. Winder, Kruti P. Maniar, Jian-Jun Wei, Dachao Liu, Denise M. Scholtens, John R. Lurain, Julian C. Schink, Barbara M. Buttin, Virginia L. Filiaci, Heather A. Lankes, Nilsa C. Ramirez, Kay Park, Meenakshi Singh, Richard W. Lieberman, Robert S. Mannel, Matthew A. Powell, Floor J. Backes, Cara A. Mathews, Michael L. Pearl, Angeles Alvarez Secord, David J. Peace, David G. Mutch, William T. Creasman, J. Julie Kim
Article
Oncology
Carol Aghajanian, Virginia Filiaci, Don S. Dizon, Jay W. Carlson, Matthew A. Powell, Angeles Alvarez Secord, Krishnansu S. Tewari, David P. Bender, David M. O'Malley, Ashley Stuckey, Jianjiong Gao, Fanny Dao, Robert A. Soslow, Heather A. Lankes, Kathleen Moore, Douglas A. Levine
GYNECOLOGIC ONCOLOGY
(2018)
Article
Oncology
Jennifer L. Moss, Jeanne Murphy, Virginia L. Filiaci, Lari B. Wenzel, Lori Minasian, Sarah M. Temkin
SUPPORTIVE CARE IN CANCER
(2019)
Meeting Abstract
Oncology
Ursula A. Matulonis, Virginia L. Filiaci, Helen Q. Huang, Marcus Randall, Byoung Kim, Paul DiSilvestro, Katherine M. Moxley, David M. O'Malley, Matthew A. Powell, Nicola M. Spirtos, Krishnansu Sujata Tewari, William Richards, John Nakayama, Margaret Steinhoff, David Gardner Mutch, David S. Miller, Lari B. Wenzel, Daniela Matei
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Meeting Abstract
Oncology
Jennifer L. Moss, Jeanne Murphy, Virginia L. Filiaci, Lari B. Wenzel, Lori M. Minasian, Sarah Madhu Temkin
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Article
Oncology
Marcus E. Randall, Virginia Filiaci, D. Scott McMeekin, Vivian von Gruenigen, Helen Huang, Catheryn M. Yashar, Robert S. Mannel, Jae-Weon Kim, Ritu Salani, Paul A. DiSilvestro, James J. Burke, Thomas Rutherford, Nick M. Spirtos, Keith Terada, Penny R. Anderson, Wendy R. Brewster, William Small, Carol A. Aghajanian, David S. Miller
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
Matthew A. Powell, Virginia L. Filiaci, Martee Leigh Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu Sujata Tewari, Larry J. Copeland, Angeles Alvarez Secord, David G. Mutch, Alessandro Santin, William Richards, David Philip Warshal, Nicola M. Spirtos, Paul Disilverstro, Olga Ioffe, David S. Miller
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Medicine, General & Internal
Daniela Matei, Virginia Filiaci, Marcus E. Randall, David Mutch, Margaret M. Steinhoff, Paul A. DiSilvestro, Katherine M. Moxley, Yong M. Kim, Matthew A. Powell, David M. O'Malley, Nick M. Spirtos, William Small, Krishnansu S. Tewari, William E. Richards, John Nakayama, Ursula A. Matulonis, Helen Q. Huang, David S. Miller
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Article
Oncology
David Scott Miller, Marcus E. Randall, Virginia Filiaci
GYNECOLOGIC ONCOLOGY
(2020)
Review
Oncology
Julian C. Schink, Virginia Filiaci, Helen Q. Huang, John Tidy, Matthew Winter, Jeanne Carter, Nancy Anderson, Katherine Moxley, Akira Yabuno, Sarah E. Taylor, Christina Kushnir, Neil Horowitz, David S. Miller
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
David S. Miller, Virginia L. Filiaci, Robert S. Mannel, David E. Cohn, Takashi Matsumoto, Krishnansu S. Tewari, Paul DiSilvestro, Michael L. Pearl, Peter A. Argenta, Matthew A. Powell, Susan L. Zweizig, David P. Warshal, Parviz Hanjani, Michael E. Carney, Helen Huang, David Cella, Richard Zaino, Gini F. Fleming
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Linda R. Duska, Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore, Kari L. Ring, Michael L. Pearl, Carolyn Y. Muller, Christina L. Kushnir, Heather A. Lankes, Megan Samuelson, Kelley S. Carrick, Anand Rajan, William H. Rodgers, Elise C. Kohn, Richard Piekarz, Kimberly K. Leslie
Summary: This study evaluated the short-term effects of MPA alone versus MPA plus entinostat on regulating progesterone receptor in women with newly diagnosed endometrioid endometrial adenocarcinoma. Although no immediate impact on PR was observed with entinostat in this short-term study, combination therapy showed better results in reducing Ki-67 levels. Lessons learned from this trial can help guide future treatment studies.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles A. Secord, David G. Mutch, Alessandro Santin, David P. Warshal, Nick M. Spirtos, Paul A. DiSilvestro, Olga B. Ioffe, David S. Miller
Summary: This phase III randomized trial compared the efficacy of paclitaxel and carboplatin (PC) with paclitaxel and ifosfamide (PI) in the treatment of uterine carcinosarcoma. The results showed that PC was not inferior to PI and should be considered as the standard treatment for uterine carcinosarcoma.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Kristina W. Thiel, Eric J. Devor, Virginia L. Filiaci, David Mutch, Katherine Moxley, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan E. McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Carol Aghajanian, Megan Samuelson, Heather A. Lankes, Robert A. Soslow, Kimberly K. Leslie
Summary: This study examined the association between p53 immunohistochemistry (IHC) and sequencing, and found that p53 IHC alone or integrated with TP53 sequencing can predict treatment outcomes. It was discovered that bevacizumab combined with chemotherapy is particularly beneficial for improving outcomes in a specific high-risk tumor genotype/phenotype identified by p53 IHC and TP53 sequencing.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Obstetrics & Gynecology
Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael Frumovitz, Samir N. Khleif, Warner K. Huh, Michael J. Birrer
GYNECOLOGIC ONCOLOGY REPORTS
(2020)